Heron Therapeutics Inc
HRTX1.745USD
+0.055+3.25%
Market hours （ET）Quotes delayed by 15 min
265.99MMarket Cap
LossP/E TTM
More Details of Heron Therapeutics Inc Company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Company Info
Ticker SymbolHRTX
Company nameHeron Therapeutics Inc
IPO dateAug 26, 1987
CEOMr. Craig Alexander Collard
Number of employees122
Security typeOrdinary Share
Fiscal year-endAug 26
Address100 Regency Forest Drive
CityCARY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27518
Phone18582514400
Websitehttps://www.herontx.com/
Ticker SymbolHRTX
IPO dateAug 26, 1987
CEOMr. Craig Alexander Collard
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Mr. Adam Morgan
Mr. Adam Morgan
Chairman of the Board
Chairman of the Board
32.89K
+19.94%
Mr. Michael Kaseta
Mr. Michael Kaseta
Independent Director
Independent Director
2.37K
-95.76%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
By RegionUSD
Name
Revenue
Proportion
United States
38.90M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.76%
Investment Advisor
24.53%
Investment Advisor/Hedge Fund
16.56%
Research Firm
3.08%
Private Equity
1.45%
Pension Fund
1.17%
Individual Investor
0.70%
Bank and Trust
0.14%
Venture Capital
0.06%
Other
16.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
350
127.68M
83.69%
-21.02M
2025Q1
384
126.94M
83.22%
-22.20M
2024Q4
390
118.52M
78.10%
-45.51M
2024Q3
400
125.21M
82.85%
-42.71M
2024Q2
402
132.96M
88.55%
-36.75M
2024Q1
402
122.65M
81.87%
-45.18M
2023Q4
413
115.58M
77.36%
-37.11M
2023Q3
417
122.12M
87.17%
-25.94M
2023Q2
428
102.54M
85.75%
-39.37M
2023Q1
447
111.46M
93.56%
-41.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
26.71M
17.51%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.23M
5.39%
+67.98K
+0.83%
Mar 31, 2025
Adage Capital Management, L.P.
7.85M
5.15%
-648.00K
-7.62%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.79M
5.11%
-114.84K
-1.45%
Mar 31, 2025
Velan Capital Investment Management LP
6.99M
4.58%
--
--
Apr 21, 2025
Palisade Capital Management, LLC
5.29M
3.47%
+1.36M
+34.65%
Mar 31, 2025
Point72 Asset Management, L.P.
4.78M
3.13%
+1.70M
+55.27%
Mar 31, 2025
Tejara Capital Ltd.
4.58M
3%
-84.14K
-1.80%
Mar 31, 2025
State Street Global Advisors (US)
3.25M
2.13%
+107.71K
+3.42%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.11M
2.04%
+98.40K
+3.26%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.5%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Principal U.S. Small-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.5%
iShares Micro-Cap ETF
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
Principal U.S. Small-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
